Menu Search
Equities

Revvity Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
0KHE:LSE

Revvity Inc

Actions
  • Price (USD)102.38
  • Today's Change-2.64 / -2.51%
  • Shares traded16.00
  • 1 Year change-8.83%
  • Beta1.0949
Data delayed at least 20 minutes, as of Feb 11 2026 14:52 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Revvity, Inc. is a provider of health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. The Company has specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more. Its segments include Life Sciences and Diagnostics. The Life Sciences segment provides products and services targeted towards the life sciences market. The segment offers instruments, reagents, software, detection and imaging technologies, and others. The Diagnostics segment develops diagnostics, tools, and applications focused on clinically oriented customers, within the reproductive health, immunodiagnostics, and applied genomics markets. The segment offers instruments, reagents, assay platforms and software to hospitals, medical labs, clinicians and medical research professionals to help improve the health of families.

  • Revenue in USD (TTM)2.86bn
  • Net income in USD239.88m
  • Incorporated1947
  • Employees11.00k
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		RVTY:NYQ since
announced		Transaction
value
Advanced Chemistry Development IncAnnounced10 Nov 202510 Nov 2025Announced11.37%--
Spring Discovery IncDeal completed03 Mar 202503 Mar 2025Deal completed-9.85%--
Data delayed at least 15 minutes, as of Feb 11 2026 21:00 GMT.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.